CA2740107A1 - Compounds for treatment of alzheimer's disease - Google Patents
Compounds for treatment of alzheimer's disease Download PDFInfo
- Publication number
- CA2740107A1 CA2740107A1 CA2740107A CA2740107A CA2740107A1 CA 2740107 A1 CA2740107 A1 CA 2740107A1 CA 2740107 A CA2740107 A CA 2740107A CA 2740107 A CA2740107 A CA 2740107A CA 2740107 A1 CA2740107 A1 CA 2740107A1
- Authority
- CA
- Canada
- Prior art keywords
- optionally substituted
- compound
- alkyl
- aryl
- heteroalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10443408P | 2008-10-10 | 2008-10-10 | |
| US61/104,434 | 2008-10-10 | ||
| US17562409P | 2009-05-05 | 2009-05-05 | |
| US61/175,624 | 2009-05-05 | ||
| PCT/US2009/060132 WO2010042796A1 (en) | 2008-10-10 | 2009-10-09 | Compounds for treatment of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2740107A1 true CA2740107A1 (en) | 2010-04-15 |
Family
ID=42100967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2740107A Abandoned CA2740107A1 (en) | 2008-10-10 | 2009-10-09 | Compounds for treatment of alzheimer's disease |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8703947B2 (enExample) |
| EP (1) | EP2349308A4 (enExample) |
| JP (1) | JP2012505241A (enExample) |
| CA (1) | CA2740107A1 (enExample) |
| WO (1) | WO2010042796A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2010002938A (es) | 2007-09-24 | 2010-04-01 | Comentis Inc | Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer. |
| JP2012521421A (ja) * | 2009-03-25 | 2012-09-13 | コメンティス，インコーポレーテッド | β−セクレターゼ活性を阻害するピロリジン化合物及びその使用方法 |
| US9096541B2 (en) * | 2012-03-29 | 2015-08-04 | Oklahoma Medical Research Foundation | Inhibition of memapsin 1 cleavage in the treatment of diabetes |
| US10085969B1 (en) * | 2016-02-12 | 2018-10-02 | University Of South Florida | Sortilin binding compounds, formulations, and uses thereof |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3630200A (en) | 1969-06-09 | 1971-12-28 | Alza Corp | Ocular insert |
| US3847770A (en) | 1972-04-10 | 1974-11-12 | Continental Can Co | Photopolymerizable compositions prepared from beta hydroxy esters and polyitaconates |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4769027A (en) | 1984-08-15 | 1988-09-06 | Burroughs Wellcome Co. | Delivery system |
| US4687610A (en) | 1986-04-30 | 1987-08-18 | E. I. Du Pont De Neumours And Company | Low crystallinity polyester yarn produced at ultra high spinning speeds |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5627165A (en) | 1990-06-13 | 1997-05-06 | Drug Innovation & Design, Inc. | Phosphorous prodrugs and therapeutic delivery systems using same |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| JP3421720B2 (ja) * | 1992-11-17 | 2003-06-30 | シチズン時計株式会社 | 角速度検出回路 |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US5354566A (en) | 1993-06-02 | 1994-10-11 | Kraft General Foods, Inc. | Preparation of yeast-leavened dough crusts |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| KR20050044407A (ko) | 2001-11-08 | 2005-05-12 | 엘란 파마슈티칼스, 인크. | N,n'-치환-1,3-디아미노-2-히드록시프로판 유도체 |
| AU2002360508A1 (en) | 2001-12-06 | 2003-06-23 | Elan Pharmaceuticals, Inc. | Substituted hydroxyethylamines |
| WO2004043916A1 (en) * | 2002-11-12 | 2004-05-27 | Merck & Co., Inc. | Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease |
| EP1641748B1 (en) | 2003-06-30 | 2013-08-28 | Merck Sharp & Dohme Corp. | N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease |
| MXPA06001559A (es) | 2003-08-08 | 2006-05-15 | Schering Corp | Inhibidores de amina ciclica bace-1 que poseen una benzamida como sustituyente. |
| US7585885B2 (en) | 2004-04-22 | 2009-09-08 | Eli Lilly And Company | Pyrrolidine derivatives useful as BACE inhibitors |
| US8436006B2 (en) | 2004-08-06 | 2013-05-07 | Jansssen Pharmaceutica N.V. | 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) |
| US7745470B2 (en) * | 2005-03-10 | 2010-06-29 | Bristol-Myers Squibb Company | Isophthalates as beta-secretase inhibitors |
| EP1866034A1 (en) | 2005-03-30 | 2007-12-19 | Boehringer Ingelheim International GmbH | Substituted 1,2-ethylendiamines, medicaments comprising said compound; their use and their method of manufacture |
| KR20080015079A (ko) | 2005-04-08 | 2008-02-18 | 코멘티스, 인코포레이티드 | 베타 세크레타제 활성을 억제하는 화합물 및 이것의 사용방법 |
| TW200804290A (en) | 2005-11-15 | 2008-01-16 | Astrazeneca Ab | Compounds and uses thereof |
| JP2009515964A (ja) * | 2005-11-16 | 2009-04-16 | メルク エンド カムパニー インコーポレーテッド | アルツハイマー病を治療するためのβ−セクレターゼ阻害剤として有用なイミダゾリジノン化合物 |
| US7902218B2 (en) * | 2006-12-12 | 2011-03-08 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinolines as β-secretase inhibitors |
| WO2010042892A1 (en) * | 2008-10-10 | 2010-04-15 | Comentis, Inc. | Pyrrolidine compounds which inhibit beta-secretase activity and methods of use thereof |
| CA2744425A1 (en) | 2008-11-20 | 2010-05-27 | Purdue Research Foundation | Quinazoline inhibitors of bace 1 and methods of using |
| WO2010065861A2 (en) | 2008-12-05 | 2010-06-10 | Purdue Research Foundation | Inhibitors of bace 1 and methods for treating alzheimer's disease |
-
2009
- 2009-10-09 WO PCT/US2009/060132 patent/WO2010042796A1/en not_active Ceased
- 2009-10-09 EP EP09819930A patent/EP2349308A4/en not_active Withdrawn
- 2009-10-09 US US13/123,157 patent/US8703947B2/en not_active Expired - Fee Related
- 2009-10-09 CA CA2740107A patent/CA2740107A1/en not_active Abandoned
- 2009-10-09 JP JP2011531201A patent/JP2012505241A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010042796A1 (en) | 2010-04-15 |
| EP2349308A4 (en) | 2012-09-12 |
| US20110195978A1 (en) | 2011-08-11 |
| EP2349308A1 (en) | 2011-08-03 |
| US8703947B2 (en) | 2014-04-22 |
| JP2012505241A (ja) | 2012-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101799005B1 (ko) | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 설프아마이드 유도체 화합물 및 이를 포함하는 약제학적 조성물 | |
| US10538498B2 (en) | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| RU2695133C1 (ru) | Производные оксадиазоламина в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция | |
| JP6081354B2 (ja) | 治療活性組成物およびそれらの使用方法 | |
| JP3022951B2 (ja) | アロイル−ピペリジン誘導体 | |
| EP3292113B1 (en) | Piperidine derivatives as hdac1/2 inhibitors | |
| KR102524421B1 (ko) | 벤젠 축합 헤테로환 유도체 및 이를 포함하는 약학 조성물 | |
| CA2744425A1 (en) | Quinazoline inhibitors of bace 1 and methods of using | |
| CA2740107A1 (en) | Compounds for treatment of alzheimer's disease | |
| HUT70048A (en) | Neurotensine-receptor-active 1-naphtyl-pyrazol-3-carboxamides process for producing them and pharmaceutical compositions containing them as active components | |
| JPWO2003029218A1 (ja) | 新規含窒素化合物及びその用途 | |
| JP2025148472A (ja) | 緑膿菌病原性因子ＬａｓＢの阻害剤 | |
| AU2009263076B2 (en) | New heterocyclic carboxamides for use as thrombin inhibitors | |
| CZ20011506A3 (cs) | Omega-amidy N-arylsulfonylaminokyselin, způsob jejich přípravy a léčivo, které je obsahuje | |
| WO2010065861A2 (en) | Inhibitors of bace 1 and methods for treating alzheimer's disease | |
| CN113660932B (zh) | 具有侧链烷基与烯基延伸的苯基衍生物及包括有其的药学组合物 | |
| EP3999493B1 (en) | Aryl-n-aryl derivatives for treating a rna virus infection | |
| MX2008015759A (es) | Derivados de pirrolidina utiles contra enfermedades que dependen de la actividad de la renina. | |
| CN102010425B (zh) | 1,4-二硫-7-氮杂螺[4,4]壬烷-8-羧酸衍生物类组蛋白去乙酰化酶抑制剂及其应用 | |
| RU2821414C2 (ru) | Арил-n-арильные производные для лечения рнк-вирусной инфекции | |
| KR20050008664A (ko) | 모폴린 유도체 및 이의 중간체의 제조를 위한 방법 | |
| HK1258700A1 (zh) | 锥虫抑制剂 | |
| WO2014164844A1 (en) | Cathepsin inhibitors | |
| ES2443538B1 (es) | Compuestos beta-lactámicos inhibidores de APAF1 | |
| EP2396334A1 (fr) | Derives de n-[(2-aza-bicyclo[2.1.1]hex-1-yl]-aryl-methyl]-benzamide, leur preparation et leur application en therapeutique |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20151009 |